ArticleFrontiers in immunology2026
Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A subset of cancer patients receiving monoclonal antibody PD-1/PD-L1 inhibitors may develop immune checkpoint inhibitor (ICI)-related neurological complications, such as ICI-related myasthenia gravis(MG)-myositis overlap syndrome and ICI-related myocarditis. Standard management typically involves intravenous immunoglobulin (IVIG), plasma exchange (PE), and high-dose corticosteroids. The use of efgartigimod, a neonatal Fc receptor blocker, for the treatment of ICI-related MG-myositis overlap syndrome remains investigational, with only four relevant cases all representing overlap syndromes (MG with myositis, with or without myocarditis) - reported to date. Objective: This report examines the therapeutic effect of efgartigimod in a patient with cervical cancer who developed ICI-related MG-myositis overlap syndrome after receiving tislelizumab, an anti-PD-1 antibody. Methods: Clinical data from the patient was collected. Relevant laboratory tests and examinations were conducted. Efgartigimod treatment was administered, and clinical severity was evaluated using standardized assessment scales. Results: A 69-year-old female with cervical cancer developed bilateral ptosis, dysarthria, and limb weakness following tislelizumab therapy. Examination revealed asymmetric ptosis, weak eye closure, and positive fatigability test. Serum creatine kinase was markedly elevated (553.82 U/L); electromyography showed myopathic changes with fibrillation potentials, while repetitive nerve stimulation was negative. Neostigmine test was positive, and anti-acetylcholine receptor antibodies were detected. She was diagnosed with ICI-related MG-myositis overlap syndrome. After four infusions of efgartigimod (10 mg/kg), creatine kinase normalized, the Activities of Daily Living (ADL) score decreased from 10 to 1, and the Quantitative Myasthenia Gravis (QMG) score improved from 16 to 5. The patient was asymptomatic at the 5 months follow-up with no need for a second treatment cycle. Conclusion: Efgartigimod produced a positive therapeutic effect in this case with ICI-related MG-myositis overlap syndrome. The therapy was well-tolerated, and no adverse events were reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.